Biotechnology

AstraZeneca’s $2 billion investment in Summit Therapeutics signals a structural shift in cancer care, uniting bispecifics and ADCs to dethrone incumbents.

Fueled by surging Iqirvo royalties and a new Medicare diagnostic code, GENFIT is quietly restructuring its pipeline to dominate intensive care hepatology.

As GLP-1s and complex biologics strain global supply chains, a massive 10-line expansion in Germany redefines the strategic value of sterile fill-and-finish.

SCIEX introduces compliance software, an open API, and high-resolution oligo kits to the BioPhase 8800, accelerating mRNA therapeutic development.

A new partnership highlights how enzymatic synthesis could solve the scaling and stereochemistry crises facing next-generation RNA therapeutics.

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

Kanazawa University researchers use high-speed microscopy to reveal how DNA's physical structure dictates its vulnerability to enzymatic destruction.

As federal research stalls, a coalition of tech and finance veterans is injecting $15 million into a nimble clinical network targeting the biological roots of Long COVID and chronic Lyme disease.

Slingshot Biosciences elevates its COO to CEO, signaling a strategic shift toward aggressive biomanufacturing scale-up and resolving cell therapy bottlenecks.

ADARx Pharmaceuticals just executed one of 2026's largest biotech debuts. Here is why institutional capital and AbbVie are betting big on the siRNA frontier.

As the global autoimmune market surges toward $322 billion, pharma giants are abandoning legacy biologics for precision therapies and cellular immune resets.

With ophthalmic trial failure rates soaring, a new CRO-led advisory model aims to replace academic vanity boards with operational reality.

With a unique off-the-shelf stem cell therapy, BOOST Pharma is poised to reshape pediatric care for osteogenesis imperfecta as it seeks Phase III partners.

Scancell leverages a costly $25M BlackRock debt facility to bridge a Nasdaq reverse merger and fuel a pivotal melanoma trial. Will the clinical data deliver?

A €12M Series A for German biotech ViferaXS highlights a strategic shift in European sovereign funding and the rise of the tech-bio equity playbook.

Crystalys Therapeutics names Tim Walbert as Chairman, signaling a bold commercial push for its de-risked gout therapy dotinurad as it enters Phase 3 trials.

Ophirex's Phase 2 trial missed its primary goals, but subgroup data and a rare FDA pathway could salvage a game-changing oral snakebite treatment.

As US policies freeze out Chinese biopharma, Altruist Biologics' flawless EMA audit reveals a pragmatic Europe prioritizing patient access over politics.

Kedrion Biopharma secures Orphan Drug Designation for QIVIGY in Stiff Person Syndrome, leveraging regulatory incentives to build a commercial moat.

As Recludix readies for the Oppenheimer showcase, its Sanofi-partnered STAT6 inhibitor signals a structural shift from biologics to oral small molecules.